CP3 HIV/HCV protease inhibitors Flashcards Preview

MSI Unit II > CP3 HIV/HCV protease inhibitors > Flashcards

Flashcards in CP3 HIV/HCV protease inhibitors Deck (7)
Loading flashcards...

characteristics of a resistant virus?

4-6 mutations, high KI(low inhibitor affinity) and an efficiency close to the WT


the biochemical basis of recommended combination therapies used against HIV and HCV

combination therapies are the standard.

both viruses (being RNA viruses) have high mutation rates and can develop resistance quickly

more facets of life cycle targeted, less likely virus will be able to adapt to completely resist


what are the sources of drug resistance and treatment failure of HIV and HCV therapes

many factors cause drug resistnace

RDRP has no proofreading, high error rate. This along wtih quick replication allows for fast changes in the genome

under certain selective pressures (spotty aherence to drug regimine) development of resistance can occur even more quickly.


treatment failure often happens as a result of (2)

development of resistance to treatment OR noncompliance by patient


what makes the development of new antiviral drugs a constant concern?

high mustation rates in both viruses - resistances emerge often


what are some barriers to a patient starting treatment?

getting them to start and stick wtih it are both challenges

-lifelong commitment as the virus is within the patients genome

-new and old treatments have many side effects that can lower quality of life

-drugs are very expensive


HIV vs HCV infection lengths?

New HCV drugs with very promising early results have been developed, making the duration for such an infection potentially much shorter than that of HIV infections

Decks in MSI Unit II Class (46):